You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
Biotech发行规模再创新高,复宏汉霖-B(2696.HK)收盘49.45港元,市值达267亿港元
格隆汇 09-25 16:45

格隆汇9月25日| 复宏汉霖-B(2696.HK)今日上市,招股价每股49.6港元,开盘价每股47.45港元,振幅5.75%。收盘价每股49.5港元,成交总量612万港元,截至今日收盘总市值约267亿港元,在今年港股尚未盈利生物医药公司的募资规模榜单中位列第一。

据悉,复宏汉霖是一家中国领先的生物医药公司,旨在为全球患者提供质高价优的创新生物药,产品覆盖肿瘤、自身免疫性疾病等领域。

截至目前,复宏汉霖已有1个产品成功上市,2个产品获得新药上市申请受理,14个产品、6个联合治疗方案在全球范围内开展20多项临床试验。公司首款重磅产品汉利康®(利妥昔单抗注射液)作为中国首个生物类似药于2019年2月获国家药监局新药上市注册批准,5月正式开始销售,公司赴港上市前已产生营收。

HLX03(阿达木单抗注射液)与HLX02(注射用曲妥珠单抗)已获国家药监局新药上市申请受理,现已纳入优先审评程序。此外,公司已陆续就HLX10与自有产品HLX04(贝伐珠单抗生物类似药)等单抗以及化疗联用开展多项肿瘤免疫联合疗法,在全球范围内开展多个临床研究。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account